Intensity Therapeutics, Inc.

NASDAQ: INTS · Healthcare · Biotechnology

PublicHQ Westport, CT · FairfieldCIK 0001567264Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 43DQ —GM —SS 30

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$11.6M

Employees

as of 2026-08-23

Market cap

$13.1M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$11.6M-$11.6M2025

Operating income-$12.0M-$12.0M2025

Total assets$14.1M$14.1M2025

Liabilities$2.2M$2.2M2025

Equity$11.9M$11.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Intensity Therapeutics, Inc.’s financial profile?

Intensity Therapeutics, Inc. earned -$11.6M in FY2025 net income.

Peers · Healthcare

BioVie Inc.——Passage Bio, Inc.——Anebulo Pharmaceuticals, Inc.——IN8bio, Inc.——Brainstorm Cell Therapeutics Inc.——Jasper Therapeutics, Inc.——

Neighbors

Fairfield →

Interactive Brokers Group, Inc.$2.4B74B Booking Holdings Inc.$26.9B79B+United Rentals, Inc.$3.7B78B+EMCOR Group, Inc.$17.0B83B+W. R. Berkley Corporation$555.8M80B+Hubbell Incorporated$5.8B83B+

Key facts

CEOLewis H. Bender

SectorHealthcare

IndustryBiotechnology

HeadquartersWestport, CT

ExchangeNASDAQ: INTS

Employees16

IPO date2023-06-30

Latest filings

8-K2026-08-11 10-Q2026-08-11 8-K2026-06-16 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-30 10-K2026-03-27 8-K2026-03-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.